Jon Paul Gockerman, MD

Professor Emeritus of Medicine
Campus mail 25154 Morris Bldg, Durham, NC 27710
Phone (919) 684-8964
Email address gocke002@mc.duke.edu

My research effort is involved in clinical research studies through the CALGB as well as several sub interests. My interest is the use of 131I MIBG in the treatment of carcinoids. We have completed a dose seeking study to determine the maximum tolerated dose. This has been completed and this paper is in preparation for publication. We plan to do an additional study of randomization in patients with this agent to see if we can determine an objective response rate in a controlled group of patients.

The secondary issue is that of high dose chemotherapy in lymphoma. We have completed a study involving use of high dose chemotherapy in a transplant setting in patients with refractory lymphoma. This study has treated over 100 patients and is in the process of being written up.

Education and Training

  • M.D., The University of Chicago, 1967

Publications

Zelenetz, Andrew D., Jeremy S. Abramson, Ranjana H. Advani, C Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, et al. “Non-Hodgkin's lymphomas.” J Natl Compr Canc Netw 9, no. 5 (May 2011): 484–560. https://doi.org/10.6004/jnccn.2011.0046.

PMID
21550968
Full Text

Bullock, Karen E., William P. Petros, Islam Younis, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, S Yousuf Zafar, et al. “A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).” Cancer Chemother Pharmacol 67, no. 2 (February 2011): 465–74. https://doi.org/10.1007/s00280-010-1507-6.

PMID
21079958
Full Text

Mowery, Y. M., J. B. Weinberg, M. N. Kennedy, K. M. Bond, J. O. Moore, M. C. Lanasa, J. P. Gockerman, et al. “LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.” Leukemia 24, no. 9 (September 2010): 1580–87. https://doi.org/10.1038/leu.2010.150.

PMID
20613784
Full Text

Crout, Christopher A., Liang-Piu Koh, Jon P. Gockerman, Joseph O. Moore, Carlos Decastro, Gwynn D. Long, Louis Diehl, et al. “Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.” Cancer Invest 28, no. 6 (July 2010): 654–60. https://doi.org/10.3109/07357901003631015.

PMID
20521909
Full Text

Zelenetz, Andrew D., Jeremy S. Abramson, Ranjana H. Advani, C Babis Andreadis, John C. Byrd, Myron S. Czuczman, Luis Fayad, et al. “NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.” J Natl Compr Canc Netw 8, no. 3 (March 2010): 288–334. https://doi.org/10.6004/jnccn.2010.0021.

PMID
20202462
Full Text

Lanasa, M. C., S. D. Allgood, A. D. Volkheimer, J. P. Gockerman, J. F. Whitesides, B. K. Goodman, J. O. Moore, J. B. Weinberg, and M. C. Levesque. “Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis.” Leukemia 24, no. 1 (January 2010): 133–40. https://doi.org/10.1038/leu.2009.192.

PMID
19946263
Full Text

Gasparetto, Cristina, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Gwynn D. Long, Mitchell E. Horwitz, et al. “"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.” Biol Blood Marrow Transplant 16, no. 1 (January 2010): 70–77. https://doi.org/10.1016/j.bbmt.2009.08.017.

PMID
19733251
Full Text

Dugan, Elizabeth, Roxanne Truax, Kellen L. Meadows, Gerald C. Blobe, Michael A. Morse, Nishan H. Fernando, Jon P. Gockerman, William P. Petros, and Herbert I. Hurwitz. “Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.” Anticancer Res 29, no. 12 (December 2009): 5149–53.

PMID
20044630
Scholars@Duke

Friedman, Daphne R., J Brice Weinberg, William T. Barry, Barbara K. Goodman, Alicia D. Volkheimer, Karen M. Bond, Youwei Chen, et al. “A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.” Clin Cancer Res 15, no. 22 (November 15, 2009): 6947–55. https://doi.org/10.1158/1078-0432.CCR-09-1132.

PMID
19861443
Full Text

Smith, S. M., J. Johnson, B. D. Cheson, G. Canellos, G. Petroni, M. Oken, D. Duggan, et al. “Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.” Leuk Lymphoma 50, no. 10 (October 2009): 1606–17. https://doi.org/10.1080/10428190903093807.

PMID
19626540
Full Text

Pages